Affiliation:
1. Department of Mechanical Engineering University of Hawaii at Manoa Honolulu Hawaii USA
2. Department of Radiation Oncology SUNY Upstate Medical University Syracuse New York USA
Abstract
AbstractBackgroundHigh‐dose‐rate (HDR) brachytherapy (BT) has been acknowledged as a widely utilized treatment for patients with intermediate‐ and high‐risk prostate cancer, despite its side effects such as edema, incontinence, and impotence. Nevertheless, the treatment is consistently limited by the potential danger of excessive irradiation to organs‐at‐risk (OARs) like the urethra, bladder, and rectum.PurposeThis study aims to introduce curvilinear catheter implantation in the prostate gland for HDR treatment. The objective is to improve the radiation dose distribution by offering access channels conformal to the prostate anatomy. This approach seeks to minimize toxicity to nearby OARs while utilizing a reduced number of needles, potentially leading to improved clinical outcomes.MethodsCurvilinear catheters were first pre‐planned for an anonymized patient using Oncentra treatment planning system (TPS) and hybrid inverse planning optimization (HIPO) algorithm. The trajectories of the catheters were then analyzed using MATLAB to extract their radius of curvature. Tendon‐driven active needles were then used to implant curvilinear catheters inside an anthropomorphic phantom.ResultsProposed curvilinear catheter implantation resulted in significant improvement in terms of dosimetric constraints to the OARs and coverage to the prostate. Tendon‐driven active needles were shown to be capable of realizing the required pre‐planned curvatures inside prostate. It was shown that the active needle can realize a desired radius of curvature and a desired trajectory with an average accuracy of 9.1 ± 8.6 and 1.27 ± 0.50 mm in air and inside a tissue‐mimicking phantom, respectively.ConclusionThis work demonstrates the feasibility of using tendon‐driven active curvilinear catheter implantation in prostate to improve the outcomes of HDR‐BT via improved radiation dose distribution to the prostate and reduced toxicity to the OARs.
Reference42 articles.
1. American Cancer Society (ACS) Cancer Statistics Center.2023. [Online]. Accessed May 1 2024.https://cancerstatisticscenter.cancer.org/?_ga=1.176033250.196666305.1484171292#!/
2. The emerging role of high‐dose‐rate (HDR) brachytherapy as monotherapy for prostate cancer;Yoshioka Y;J Radiat Res,2013
3. High dose rate prostate brachytherapy: an overview of the rationale, experience and emerging applications in the treatment of prostate cancer;Challapalli A;Br J Radiol,2012
4. Long‐term quality‐of‐life outcomes after prostate radiation therapy with or without high‐dose‐rate brachytherapy boost: post hoc analysis of TROG 03.04 RADAR;Ong WL;Int J Radiat Oncol Biol Phys,2023
5. Androgen suppression combined with elective nodal and dose escalated radiation therapy (the ASCENDE‐RT Trial): an analysis of survival endpoints for a randomized trial comparing a low‐dose‐rate brachytherapy boost to a dose‐escalated external beam boost F;Morris WJ;Int J Radiat Oncol Biol Phys,2017
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献